Celcuity falls 7.6% as traders fade post-update rally ahead of July FDA decision
Celcuity shares slid as investors repositioned after the company’s March 25, 2026 earnings/corporate update and with no new trial or regulatory catalyst announced today. The stock has also been volatile into the next major binary event: the FDA’s July 17, 2026 PDUFA decision for gedatolisib under Priority Review.
1) What’s moving the stock
Celcuity (CELC) dropped about 7.6% in the latest session, a move that appears driven by position-trimming and profit-taking after recent company communications rather than a single fresh headline. The company had just held its fourth-quarter and full-year 2025 results call and corporate update on March 25, 2026, which can reset near-term expectations and trigger tactical selling in a high-momentum biotech name. (globenewswire.com)
2) The bigger catalyst investors are trading around
The next hard, market-moving milestone remains regulatory: Celcuity’s New Drug Application for gedatolisib was accepted with Priority Review, setting a PDUFA goal date of July 17, 2026. With a binary FDA outcome ahead, biotech traders often reduce exposure on down days—especially after sharp multi-month runs—while waiting for incremental de-risking events or clearer read-throughs. (stocktitan.net)
3) Why the tape can swing hard in CELC
CELC has elevated short positioning relative to its float, which can amplify day-to-day moves as liquidity thins and both long and short holders adjust ahead of catalysts. Short interest was reported at roughly 9.11 million shares, about 23% of public float as of February 27, 2026, a setup that can intensify volatility in either direction when sentiment shifts. (marketbeat.com)